SUBSCRIBE
SUBSCRIBE
News   Business

Molecular Response (MRL) Announces Key Agreement in Translational Oncology with SuperGen, Inc.

July 27, 2011 | 
1 min read
SAN DIEGO--(BUSINESS WIRE)--Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics, announced today an agreement with SuperGen, Inc.
Alliances
MORE ON THIS TOPIC
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Amgen lays off around 40 employees
July 26, 2026
 · 
70 min read
 · 
BioSpace Editorial Staff
pipeline infographic, industrial background, oil water gas transportation yellow pipes, plumbing system vector illustration
Drug Development
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
July 24, 2026
 · 
3 min read
 · 
Gabrielle Masson
A two old parchment scrolls with a quill in a inkwell on a white background
IPO
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
July 24, 2026
 · 
3 min read
 · 
Tristan Manalac
A crowd of abstract multicolored silhouettes of people and conversational bubbles above them, made in the style of a collage. A metaphor for society and cooperation.
Regulatory
Amgen deploys patients to defend troubled Tavneos in FDA hearing request
July 24, 2026
 · 
4 min read
 · 
Annalee Armstrong